Market Overview - The Chinese medicine sector experienced a decline of 0.3% on December 31, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Ziling: closed at 4.35, up 2.84% with a trading volume of 476,800 shares and a turnover of 207 million yuan [1] - Guohan Pharmaceutical: closed at 11.21, up 2.66% with a trading volume of 48,400 shares and a turnover of 54.01 million yuan [1] - Major decliners included: - *ST Changyao: closed at 0.87, down 8.42% with a trading volume of 828,300 shares and a turnover of 73.23 million yuan [2] - ST Huluwa: closed at 7.62, down 4.63% with a trading volume of 176,200 shares and a turnover of 134 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 399 million yuan from institutional investors, while retail investors contributed a net inflow of 376 million yuan [2] - The sector's capital flow details indicate: - Dong'e Ejiao had a net inflow of 27.6 million yuan from institutional investors, but a net outflow of 14.69 million yuan from speculative funds [3] - Guohan Pharmaceutical experienced a net inflow of 8.03 million yuan from institutional investors, but a net outflow of 9.69 million yuan from retail investors [3]

Group 1 - Shengxin Lithium Energy plans to acquire 30% equity of Qicheng Mining for 2.08 billion yuan, aiming to hold 100% of Qicheng Mining post-transaction [1] - Qicheng Mining holds a 70.97% stake in Huirong Mining, which has confirmed Li2O resources of 989,600 tons with an average grade of 1.62% [1] - The acquisition is part of Shengxin Lithium Energy's strategy to enhance its lithium resource portfolio [1] Group 2 - Zhongju High-tech intends to repurchase shares worth 300 million to 600 million yuan, with a maximum price of 26 yuan per share [2] - Baili Tianheng plans to repurchase shares valued between 100 million to 200 million yuan, with a maximum price of 546 yuan per share [3] Group 3 - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for approximately 264 million yuan [5] - Yilake Co. will be included in the consolidated financial statements of China Aluminum post-acquisition [5] Group 4 - Salt Lake Co. intends to acquire 51% of Wuku Salt Lake for 4.605 billion yuan, aiming to become the controlling shareholder [6] - The acquisition is part of Salt Lake Co.'s strategy to accelerate the development of a world-class salt lake industry base [6] Group 5 - Cobalt Co. plans to invest 1.741 billion yuan in the expansion of a lead-zinc mining project with an annual capacity of 1.65 million tons [7] - The investment aims to enhance the mining capacity of the Cobalt Co.'s subsidiary [7] Group 6 - Tianyuan Co. is investing 1.483 billion yuan in a new chlorination titanium dioxide project with an annual capacity of 100,000 tons [9] - The project is part of Tianyuan Co.'s expansion strategy in the titanium dioxide market [9] Group 7 - Jiangbo Long plans to purchase the remaining 19% equity of its subsidiary Zilia Eletrônicos for approximately 46.08 million USD [26] - The acquisition aims to strengthen Jiangbo Long's position in the storage business and expand its international investment layout [26] Group 8 - China National Airlines intends to purchase 60 Airbus A320NEO series aircraft at a total catalog price of approximately 9.53 billion USD [33] - The aircraft are scheduled for delivery between 2028 and 2032 [33]

Group 1 - The article highlights that small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them more likely to become market leaders [1] - As of December 30, there are 949 stocks with a circulating market value below 3 billion yuan, and 374 stocks with a circulating market value below 2 billion yuan [1] - A total of 1,632 stocks have a total market value below 5 billion yuan, with 580 stocks having a total market value below 3 billion yuan [1] Group 2 - The three stocks with the smallest circulating market values are *ST Changyao at 333 million yuan, *ST Aowei at 453 million yuan, and Kuntai Co. at 637 million yuan [1] - The three stocks with the smallest total market values are *ST Changyao at 333 million yuan, *ST Aowei at 510 million yuan, and Dongtong Tui at 686 million yuan [1] - A detailed list of stocks with circulating market values below 2 billion yuan includes various sectors such as pharmaceuticals, defense, automotive, and more, with notable examples like *ST Changyao and *ST Aowei [1][2]

截至12月30日收盘，*ST长药的股价报0.95元/股，下跌19.49%，总市值约3亿元。 12月30日晚间，长江医药控股股份有限公司（以下简称*ST长药，300391.SZ）发布公告称，公司股票 收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1元而被终止上市。同时，公司因涉嫌定 期报告等财务数据虚假记载被证监会立案调查，可能触及重大违法强制退市情形。 此外，*ST长药2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实施财务类强制退 市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税风险。 公告显示，12月26日，*ST长药收到中国证监会下发的《行政处罚事先告知书》，认定公司2021年、 2022年、2023年的年度报告存在虚假记载。 12月29日晚间，*ST长药发布公告称，收到十堰中院送达的《民事裁定书》和《决定书》，法院裁定不 予受理十堰市郧胥工贸有限公司对公司的重整申请，决定依法终结公司预重整程序。法院认为，依照相 关规定，长药控股在预重整期间未能提交预重整方案，明显缺乏重整可行性。同日，公司收到另一份法 院的《民事裁定书》，裁定终止*ST长药的 ...

Core Viewpoint - *ST Changyao is facing multiple delisting risks due to its stock price falling below par value, suspected financial data falsification, and an expected negative net asset at the end of the period, which has attracted significant market attention [1] Group 1: Stock Price and Listing Rules - On December 30, 2025, *ST Changyao's stock closed at 0.95 yuan per share, marking the first instance of the closing price falling below 1 yuan [3] - According to the Shenzhen Stock Exchange's listing rules, if the stock price remains below 1 yuan for twenty consecutive trading days, it will face delisting [3] - The company is required to issue a risk warning announcement the day after the first occurrence of the stock price falling below 1 yuan and must continue to disclose risks if the situation persists [3] Group 2: Regulatory Investigations and Financial Irregularities - On November 7, 2025, *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected financial data falsification [3] - The CSRC issued a prior notice of administrative penalty on December 26, 2025, indicating that the company had inflated its revenue by 215 million yuan, 284 million yuan, and 234 million yuan for the years 2021, 2022, and 2023, respectively [4] - The inflated profits for the same years were reported as 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [4] Group 3: Financial Condition and Risks - As of the end of 2024, the audited net assets attributable to shareholders were -433 million yuan, leading to a delisting risk warning [5] - By the end of the third quarter of 2025, the net assets further declined to -643 million yuan, with an expectation of negative net assets by December 31, 2025, which could trigger financial delisting conditions [5] - The company is involved in 152 litigation and arbitration cases, with a total amount of 1.932 billion yuan, which is 446% of the latest audited net assets [5] - The company has significant interest-bearing debts of 1.106 billion yuan, with overdue debts amounting to 390 million yuan, impacting its repayment capacity [5]

Core Viewpoint - *ST Changyao's stock price has fallen below 1 yuan for the first time, potentially leading to delisting due to continuous trading below this threshold and ongoing investigations by the China Securities Regulatory Commission (CSRC) for financial misconduct [2][4][6] Financial Performance - The company reported a negative net asset value of -433 million yuan for the end of 2024, which could trigger mandatory delisting if the negative trend continues into 2025 [5] - The audited net profits for 2022, 2023, and 2024 were -76.39 million yuan, -632 million yuan, and -569 million yuan respectively, indicating a consistent decline in financial performance [5] Legal and Regulatory Issues - The CSRC has identified that *ST Changyao inflated revenue and profits for three consecutive years, leading to proposed fines of 10 million yuan for the company and 31 million yuan for 14 responsible individuals [6] - The company is under investigation for potential major violations that could result in delisting, with the Shenzhen Stock Exchange initiating delisting procedures [6] Court Proceedings - The company faced a court ruling that rejected its restructuring application, indicating a lack of feasibility for reorganization [3] - The court also terminated the substantive merger restructuring process for *ST Changyao and six other companies, declaring them bankrupt [3]

在相继披露了法院裁定不予受理重整申请暨子公司宣告破产、公司股票可能被实施重大违法强制退市相关风险、公司股票被叠加实施退市风险警示的公告 后，*ST长药（300391）的股价在12月30日盘中一度跌停，当天收盘价报0.95元/股，下跌19.49%。 30日晚间，*ST长药发布公告，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1元而被终止上市。同时，公司因涉嫌定期报告等 财务数据虚假记载被证监会立案调查，可能触及重大违法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实 施财务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税风险。 对于股价跌破1元、法院裁定不予受理重整申请的影响，以及后续措施等，上证报记者以投资者身份致电*ST长药投资者专线，公司相关人士回应："不出 意外是要退市，暂无应对措施。" 在涉嫌触及重大违法强制退市情形前，*ST长药已存在财务类强制退市风险。 同时，据公司2022年、2023年、2024年年度报告，公司2022年、2023年、2024年度经审计的扣除非经常性损益后的净利润分别为-763 ...

人民财讯12月30日电，*ST长药（300391）12月30日公告，12月30日，公司股票收盘价格为0.95元/股， 根据《深圳证券交易所创业板股票上市规则》第10.2.1条的规定，若公司出现连续二十个交易日的股票 收盘价均低于1元，公司股票将被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会 立案调查，可能触及重大违法强制退市情形；公司2024年度期末净资产为负，若2025年度期末净资产继 续为负，将被实施财务类强制退市。此外，公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险， 账户冻结风险以及大额欠税风险。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 *ST长药(300391.SZ)公告称，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1 元而被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会立案调查，可能触及重大违 法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实施财 务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税 风险。 ...

*ST长药(300391.SZ)公告称，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1 元而被终止上市。同时，公司因涉嫌定期报告等财务数据虚假记载被证监会立案调查，可能触及重大违 法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实施财 务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税 风险。 ...